Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, South Korea; East-West Medical Research Institute, Kyung Hee University, Seoul, South Korea.
Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, South Korea.
Pancreatology. 2024 Jun;24(4):584-591. doi: 10.1016/j.pan.2024.04.005. Epub 2024 Apr 25.
We aimed to assess the diagnostic utility of an immunohistochemical panel including calcium-binding protein P, p53, Ki-67, and SMAD family member 4 and K-ras mutation for diagnosing pancreatic solid lesion specimens obtained by endoscopic ultrasound-guided fine-needle biopsy and to confirm their usefulness in histologically inconclusive cases.
Immunohistochemistry and peptide nucleic acid-clamping polymerase chain reaction for K-ras mutation were performed on 96 endoscopic ultrasound-guided fine-needle biopsy specimens. The diagnostic efficacy of each marker and the combination of markers was calculated. The diagnostic performances of these markers were evaluated in 27 endoscopic ultrasound-guided fine-needle biopsy specimens with histologically inconclusive diagnoses. A classification tree was constructed.
K-ras mutation showed the highest accuracy and consistency. Positivity in more than two or three of the five markers showed high diagnostic accuracy (94.6 % and 93.6 %, respectively), and positivity for more than three markers showed the highest accuracy for inconclusive cases (92.0 %). A classification tree using K-ras mutation, Ki-67, S100P, and SMAD4 showed high diagnostic performance, with only two misclassifications in inconclusive cases.
K-ras mutation detection via peptide nucleic acid-clamping polymerase chain reaction is a stable and accurate method for distinguishing between pancreatic ductal adenocarcinoma and non-pancreatic ductal adenocarcinoma lesions. A classification tree using K-ras mutation, Ki-67, S100P, and SMAD4 helps increase the diagnostic accuracy of cases that are histologically difficult to diagnose.
我们旨在评估包括钙结合蛋白 P、p53、Ki-67、SMAD 家族成员 4 和 K-ras 突变在内的免疫组织化学组合在诊断经内镜超声引导细针活检获得的胰腺实体病变标本中的应用,并确认其在组织学不确定病例中的有用性。
对 96 例经内镜超声引导细针活检标本进行免疫组织化学和肽核酸夹聚合酶链反应检测 K-ras 突变。计算每个标志物和标志物组合的诊断效能。在 27 例组织学不确定的经内镜超声引导细针活检标本中评估这些标志物的诊断性能。构建分类树。
K-ras 突变显示出最高的准确性和一致性。五个标志物中超过两个或三个标志物阳性显示出较高的诊断准确性(分别为 94.6%和 93.6%),而对于不确定病例,超过三个标志物阳性的准确性最高(92.0%)。使用 K-ras 突变、Ki-67、S100P 和 SMAD4 的分类树显示出较高的诊断性能,在不确定病例中仅有两个误分类。
通过肽核酸夹聚合酶链反应检测 K-ras 突变是区分胰腺导管腺癌和非胰腺导管腺癌病变的一种稳定且准确的方法。使用 K-ras 突变、Ki-67、S100P 和 SMAD4 的分类树有助于提高组织学上难以诊断病例的诊断准确性。